Drugs / Ferric Pyrophosphate Liposomal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05714176 | Feb 2023 → Jan 2024 | chronic kidney disease | Menoufia University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05957328 Comparator | Aug 2023 → Aug 2024 | iron deficiency anemia | All India Institute of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ferric Pyrophosphate Liposomal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05957328 ↗ |
| Known as | Novoferr | “30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.” NCT05714176 ↗ |
| Route | Oral | “receive oral liposomal iron” NCT05714176 ↗ |